Resources
About Us
Attention Deficit Hyperactivity Disorder (ADHD) Market Size, Share, Forecast, & Trends Analysis by Drug Type (Stimulants, Non-Stimulants), Age Group (Pediatric-Adolescents, Adults), Distribution Channel (Retail, Hospital, Online Pharmacies) - Global Forecast to 2031
Report ID: MRHC - 1041449 Pages: 130 Jan-2025 Formats*: PDF Category: Healthcare Delivery: 24 to 72 Hours Download Free Sample ReportThe growth of this market is driven by the increasing awareness of attention deficit hyperactivity disorder (ADHD), rising incidence of ADHD, and expansion of ADHD diagnoses across age groups. In addition, advancements in treatment options and growth of non-pharmacological treatments are expected to create growth opportunities for the players operating in the ADHD market. Moreover, the growing focus on personalized treatment and growth of digital therapeutics are prominent trends in the market.
In recent years, there has been growing awareness about mental health and ADHD among parents, educators, and healthcare professionals. If left untreated, ADHD can significantly impact a person’s life. During the COVID-19 pandemic, mental health such as stress, anxiety, and depression surged, leading to more comprehensive diagnostic evaluations. These evaluations revealed a notable increase in ADHD cases.
According to the Centers for Disease Control and Prevention (CDC), in 2022, approximately 7 million children aged 3-17 in the U.S. have ever been diagnosed with ADHD compared to 2016. ADHD diagnosis in children varies from 6% to 16%. This surge reflects both a broader recognition of the disorder and improved access to healthcare and diagnostic tools.
Moreover, public health campaigns and educational initiatives aimed at destigmatizing ADHD are encouraging individuals to pursue diagnosis and treatment. This shift in perception has led to a reduction in the stigma associated with ADHD, encouraging more people to pursue diagnosis and treatment. As awareness grows, there is increasing recognition that ADHD extends into adulthood, leading to a surge in demand for adult ADHD treatments, including medications and counseling. Thus, an increase in ADHD awareness is expected to drive the growth of this market across the globe.
ADHD, a neurodevelopmental disorder characterized by symptoms such as inattention, hyperactivity, and impulsivity, is becoming more commonly diagnosed, particularly in children. As awareness of the disorder expands, more parents, educators, and healthcare providers are recognizing its signs, contributing to a rise in diagnosis rates.
The demand for ADHD medications, including stimulants such as methylphenidate and amphetamines, has surged as these treatments are often the first line of intervention. Additionally, non-stimulant medications and behavioral therapy options are also in higher demand, reflecting a broader approach to managing the condition.
According to the Centers for Disease Control and Prevention (CDC), in 2023, approximately 15.5 million U.S. adults had an ADHD diagnosis, with around half of them receiving their diagnosis in adulthood. In addition, among adults with ADHD, around one-third use stimulant medications, while approximately 70% report difficulties in filling their prescriptions due to ongoing medication shortages.
The prevalence of ADHD in children is also significant. Between 2020 and 2022, the CDC reported that 11.3% of children aged 5–17 years had been diagnosed with ADHD. The condition is more prevalent among boys (14.5%) compared to girls (8.0%). The increasing recognition of ADHD's impact on quality of life underscores the necessity for effective interventions and support systems. Therefore, the rising incidence of ADHD boosts the demand for ADHD drugs.
The increasing research, innovation, and evolving patient needs are driving the advancement of ADHD treatment. Traditional treatments, such as stimulant medications, remain common, but there is increasing demand for alternative therapies due to concerns over side effects, dependence, and long-term efficacy. This has spurred the development of non-stimulant medications, digital therapeutics, and personalized treatment approaches.
Non-stimulant medications have gained traction as viable alternatives for managing ADHD symptoms. They are particularly beneficial for patients who are sensitive to stimulant side effects or have a history of substance abuse. These medications generally do not cause agitation or insomnia and have a smoother onset and offset compared to stimulants. In addition, non-stimulants can provide more stable symptom control throughout the day without the abrupt highs and lows associated with stimulants. Non-stimulant options like atomoxetine and viloxazine are becoming increasingly important for those who require alternatives due to side effects or personal preferences. In May 2024, Tris Pharma, Inc. (U.S.) Onyda XR, a liquid, nonstimulant ADHD, was approved by the FDA for treatment of ADHD. This diversification in treatment options enhances the overall management of ADHD, which provides growth opportunities for the ADHD market.
Based on drug type, the attention deficit hyperactivity disorder market is segmented into stimulants and non-stimulants. In 2025, the stimulants segment is expected to account for a larger share of the attention deficit hyperactivity disorder market primarily due to the rapid onset of stimulants, ability to target symptoms by increasing dopamine levels and clinically suggested by healthcare professionals. Additionally, many studies have shown that stimulants can reduce ADHD in approximately 70-80% of users, making them highly effective as a first-line treatment option for both children and adults.
Moreover, non-stimulants have slower onset and face challenges in gaining the same level of efficiency as stimulants. This attributes to consumers and healthcare professionals to shift towards stimulants. Furthermore, rising awareness regarding mental health diseases, recent innovations in ADHD stimulants, and strong efficiency of drugs are expected to support the growth of this market.
Based on geography, the attention deficit hyperactivity disorder market is majorly segmented into five regions: North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. In 2024, North America accounted for the largest share of the global attention deficit hyperactivity disorder market, followed by Europe and Asia-Pacific. North America's large market share is attributed to several key factors, including the large population with mental health issues, increasing prescription rates, rising product innovations, growing incidence of ADHD in the U.S., and growing demand for stimulants.
Moreover, this region is slated to register the highest CAGR during the forecast period of 2024–2031 due to the approval and commercialization of new drugs, growing spending on ADHD treatment, rising diagnosis among adults, growing focus on personalized treatments, and technological integration like digital therapeutics.
The report includes a competitive landscape based on an extensive assessment of the key strategic developments that led market participants to adopt over the past three years.
The key players profiled in the attention deficit hyperactivity disorder market report are Eli Lilly and Company (U.S.), Lupin Limited (India), Mallinckrodt plc (Ireland), Tris Pharma, Inc (U.S.), Takeda Pharmaceutical Company Limited (Japan), Zevra Therapeutics, Inc. (U.S.), Novartis AG (Switzerland), Aytu Biopharma, Inc. (U.S.), Otsuka Pharmaceutical Co., Ltd. (Japan), Johnson & Johnson (U.S.), Alora Pharmaceuticals, LLC (U.S.), Supernus Pharmaceuticals, Inc. (U.S.), and Noven Pharmaceuticals, Inc. (U.S.).
Particulars |
Details |
Number of Pages |
145 |
Format |
|
Forecast Period |
2024–2031 |
Base Year |
2023 |
CAGR |
6% |
Market Size |
USD 23.66 Billion by 2031 |
Segments Covered |
By Drug Type
By Age Group
By Distribution Channel
|
Countries Covered |
North America (U.S., Canada), Europe (Germany, U.K., Spain, Italy, France and Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South Korea and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentina, and Rest of Latin America), and the Middle East & Africa (Saudi Arabia, UAE, and Rest of Middle East & Africa) |
Key Companies |
Eli Lilly and Company (U.S.), Lupin Limited (India), Mallinckrodt plc (Ireland), Tris Pharma, Inc (U.S.), Takeda Pharmaceutical Company Limited (Japan), Zevra Therapeutics, Inc. (U.S.), Novartis AG (Switzerland), Aytu Biopharma, Inc. (U.S.), Otsuka Pharmaceutical Co., Ltd. (Japan), Johnson & Johnson (U.S.), Alora Pharmaceuticals, LLC (U.S.), Supernus Pharmaceuticals, Inc. (U.S.), and Noven Pharmaceuticals, Inc (U.S.). |
The global attention deficit hyperactivity disorder market size was valued at $15.73 billion in 2024.
The market is projected to grow from $15.73 billion in 2024 to $23.66 billion by 2031.
The attention deficit hyperactivity disorder market analysis indicates significant growth, reaching $23.66 billion by 2031, at a compound annual growth rate (CAGR) of 6% from 2024 to 2031.
The key companies operating in this market include Eli Lilly and Company (U.S.), Lupin Limited (India), Mallinckrodt plc (Ireland), Tris Pharma, Inc (U.S.), Takeda Pharmaceutical Company Limited (Japan), Zevra Therapeutics, Inc. (U.S.), Novartis AG (Switzerland), Aytu Biopharma, Inc. (U.S.), Otsuka Pharmaceutical Co., Ltd. (Japan), Johnson & Johnson (U.S.), Alora Pharmaceuticals, LLC (U.S.), Supernus Pharmaceuticals, Inc. (U.S.), and Noven Pharmaceuticals, Inc (U.S.).
The prominent market trends in attention deficit hyperactivity disorder are growing focus on personalized treatment and growth of digital therapeutics.
By drug type, the stimulants segment is projected to hold a larger market share.
By age group, the pediatric-adolescents age-group is expected to dominate the market.
By distribution channel, the retail pharmacies segment is poised to record the dominant position in the market.
By region, North America will hold the largest share of the global attention deficit hyperactivity disorder market share in 2025. Moreover, this region is expected to grow at the highest CAGR, mainly due to the approval and commercialization of new drugs, growing spending on ADHD treatment, and rising diagnosis among adults.
The primary drivers of attention deficit hyperactivity disorder market growth include the increasing awareness of ADHD, rising incidence of ADHD, and expansion of ADHD diagnoses across age groups.
Published Date: Aug-2017
Published Date: Mar-2024
Published Date: Jan-2024
Published Date: Nov-2024
Published Date: Jun-2024
Please enter your corporate email id here to view sample report.
Subscribe to get the latest industry updates